Skip to main content

Table 1 Patient clinical characteristics at the start of MTX administration

From: Preliminary study for predicting better methotrexate efficacy in Japanese patients with rheumatoid arthritis

No. of patients

21

Women, %

85.7

Age (years)

57 (33–69)

DAS28-CRP

4.00 (2.31–6.66)

CRP (mg/dL)

1.26 (0.07–11.53)

ESR (mm/h)

30 (11–95)

RF (IU/mL)

85 (3–260)

Scr (mg/dL)

0.60 (0.45–1.02)

Duration of RA (months)

28 (3–237)

DMARD adminstration history (%)

73.7

  1. Value at the start of MTX admistration: median (minimum–maximum)
  2. MTX methotrexate, DAS28-CRP Disease Activity Score-28 joints–C-reactive protein, ESR erythrocyte sedimentation rate, RF rheumatoid factor, Scr serum creatinine, RA rheumatoid arthritis, DMARD disease-modifying antirheumatic drug